Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: Design of and rationale for the ABSORB III randomized trial

American Heart Journal

Volumn 170, Issue 4, 2015, Pages 641-651.e3

  Kereiakes, Dean J ^a   Ellis, Stephen G ^b   Popma, Jeffrey J ^c   Fitzgerald, Peter J ^d   Samady, Habib ^e   Jones Mcmeans, Jennifer ^f   Zhang, Zhen ^f   Cheong, Wai Fung ^f   Su, Xiaolu ^f   Ben Yehuda, Ori ^g   Stone, Gregg W ^g  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY HOSPITAL   (United States)

^f ABBOTT VASCULAR   (United States)

^g New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIORESORBABLE SCAFFOLD; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENTING; EVEROLIMUS ELUTING CORONARY STENT; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANGIOCARDIOGRAPHY; BIODEGRADABLE IMPLANT; BLOOD; CLINICAL TRIAL; DRUG ELUTING STENT; FEMALE; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; PROSTHESIS; TIME; TISSUE SCAFFOLD; TREATMENT OUTCOME;

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ABSORBABLE IMPLANTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; TIME FACTORS; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84941940686     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.07.013     Document Type: Article

References (19)

1. A.J. Kirtane, A. Gupta, S. Iyengar, and et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies Circulation 119 2009 3198 3206
2. P.W. Serruys, M.J. Kutryk, and A.T. Ong Coronary-artery stents N Engl J Med 354 2006 483 495
3. S. Bangalore, S. Kumar, M. Fusaro, and et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials Circulation 125 2012 2873 2891
4. T. Palmerini, G. Biondi-Zoccai, D. Della Riva, and et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
5. M. Joner, A.V. Finn, A. Farb, and et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202
6. G. Nakazawa, F. Otsuka, M. Nakano, and et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
7. F. Otsuka, M. Vorpahl, M. Nakano, and et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans Circulation 129 2014 211 223
8. P.W. Serruys, Y. Onuma, J.A. Ormiston, and et al. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes Circulation 122 2010 2301 2312
9. P.W. Serruys, J.A. Ormiston, Y. Onuma, and et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods Lancet 373 2009 897 910
10. J.P. Lane, L.E. Perkins, A.J. Sheehy, and et al. Lumen gain and restoration of pulsatility after implantation of a bioresorbable vascular scaffold in porcine coronary arteries JACC Cardiovasc Interv 7 2014 688 695
11. F. Otsuka, E. Pacheco, L.E. Perkins, and et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model Circ Cardiovasc Interv 7 2014 330 342
12. P.W. Serruys First report of the three year clinical and multi-modality imaging results of the ABSORB trial evaluating the Absorb everolimus eluting bioresorbable vascular scaffold in the treatment of patients with de novo native coronary artery lesions J Am Coll Cardiol 61 2013 E1731 [abstract]
13. A. Karanasos, C. Simsek, M. Gnanadesigan, and et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold J Am Coll Cardiol 64 2014 2343 2356
14. D. Carrie ABSORB EXTEND: An interim report on the 24-month clinical outcomes from the first 450 patients enrolled J Am Coll Cardiol 63 2014 A1882 [abstract]
15. P.W. Serruys, B. Chevalier, D. Dudek, and et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial Lancet 385 2015 43 54
16. B. Chevalier, M.J. Grundeken, R. White, and et al. Differences in the occurence of new or worsening angina between the ABSORB bioresorbable vascular scaffold and XIENCE metallic stent: a post-hoc analysis of the ABSORB II randomized trial J Am Coll Cardiol 65 2015 A1707 [abstract]
17. G.S. Mintz, S.E. Nissen, W.D. Anderson, and et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol 37 2001 1478 1492
18. D.E. Cutlip, S. Windecker, R. Mehran, and et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
19. D.J. Kereiakes, D.E. Cutlip, R.J. Applegate, and et al. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) J Am Coll Cardiol 56 2010 2084 2089